ScisGo HLA v6

Phased 3-field HLA typing in a single assay using proven Scisco Genetics technology and the GeMS analysis software suite.

Highlights

  • Class I HLA -A, -B, -C exons 1-7
  • Class II HLA-DRB1345, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1 exons 1-4
  • Phased 3-field typing across all loci
  • All known null alleles detected
  • Simple, PCR-only protocol
  • No robotics
  • Total DNA input as low as 10 ng
  • DNA from a variety of sources including saliva, buccal swabs, and dried blood spots
  • DNA to Data in 30 hours

Overview

The human leukocyte antigens (HLA) are intimately involved in the innate and adaptive immune responses, communicating normal and abnormal cellular status to surveying immune cells. These highly polymorphic genes can greatly affect the outcome of hematopoietic cell and solid organ transplantation, in addition to their consequential roles in infectious disease, autoimmunity, and cancer.

Our NGS solution for HLA class I and II typing is carried out via multiplex PCR of HLA specific amplicons. Exon and flanking intron sequences from the HLA genes are amplified in 4 reactions, simultaneously tagged with index sequences (to distinguish samples), pooled, and sequenced. Data can be stored and analyzed on the cloud and derivative typing data can be visualized on your desktop computer.


ScisGo CHIM v4

Post-transplant analysis of the donor/recipient origin of white blood cells in peripheral blood and/or marrow.

Highlights

  • All chromosomes sampled
  • Next Generation Sensitivity, down to 0.1%
  • Simple, PCR-only protocol
  • No robotics
  • Total DNA input as low as 0.5 ng (equivalent to ~ 500 cells)
  • Data analysis provides 95% confidence intervals and sensitivity levels.
  • DNA to Data in 12 hours

Overview

A test for chimerism after allogeneic hematopoietic cell transplantation (HCT) is routinely performed as a prognostic measure of engraftment and related clinical outcomes. Chimerism tests employ methods commonly used in identity testing to distinguish and quantitate donor and recipient cells present in blood, bone marrow, and various tissues.

Our 4-reaction Chimerism assay employs simple to perform laboratory steps and takes advantage of Next Generation Sequencing (NGS) technology to advance testing into the next generation of sensitivity and accuracy. Our assay can be adjusted for capacity and sensitivity by varying the number of reactions used and samples analyzed. Turnaround times from DNA to data are comparable to other commonly used methodologies.